Esperion Therapeutics Inc. (NASDAQ:ESPR) saw a downside of -3.38% to close Tuesday at $1.43 after subtracting -$0.05 on the day. The 5-day average trading volume is 2,663,660 shares of the company’s common stock. It has gained $1.6700 in the past week and touched a new high 1 time within the past 5 days. An average of 3,062,300 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 3,007,168.
ESPR’s 1-month performance is -2.72% or -$0.1000 on its low of $1.3550 reached on 07/27/23. The company’s shares have touched a 52-week low of $1.12 and high of $8.87, with the stock’s rally to the 52-week high happening on 01/10/23. YTD, ESPR has lost -77.05% or -$4.8000 and has reached a new high 4 times. However, the current price is down -83.88% from the 52-week high price.
Insider Transactions
ESPR stock investors last saw insider trading activity on Aug 18.Warren Eric (Chief Commercial Officer) most recently sold 243 shares at $1.41 per share on Aug 18. This transaction cost the insider $344. Chief Commercial Officer, Warren Eric, sold 106 shares at a price of $1.58 on Jul 19. Then, on Jun 21, Chief Commercial Officer Warren Eric sold 603 shares at a price of $1.48 per share. This transaction amounted to $894.
Valuation Metrics
ESPR stock has a beta of 0.14. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 1.73.
Esperion Therapeutics Inc.’s quick ratio for the period ended June 29 was 1.70, with the current ratio over the same period at 2.20.. In terms of profitability, the gross margin trailing 12 months is 66.90%. The trailing 12-month EBITDA margin is -237.17%. The firm’s gross profit as reported stood at $48.51 million against revenue of $75.47 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income shrunk -32.8% to -$49.94 million, while revenue of -$61.72 million was -23.59% off the previous quarter. Analysts expected ESPR to announce -$0.61 per share in earnings in its latest quarter, but it posted -$0.46, representing a 24.60% surprise. EBITDA for the quarter stood at more than -$36.66 million. ESPR stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 606.6 million, with total debt at $522.9 million. Shareholders hold equity totaling $106.99 million.
Let’s look briefly at Esperion Therapeutics Inc. (ESPR) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 August was 37.10% to suggest the stock is trending Neutral, with historical volatility in this time period at 110.23%.
The stock’s 5-day moving average is $1.4660, reflecting a -12.80% or -$0.2100 change from its current price. ESPR is currently trading -0.69% above its 20-day SMA, -19.66% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +10.00% and SMA200 by-82.21%.
Stochastic %K and %D was 13.35% and 13.46% and the average true range (ATR) pointed at 0.1382. The RSI (14) points at 42.37%, while the 14-day stochastic is at 12.20% with the period’s ATR at 0.1391. The stock’s 9-day MACD Oscillator is pointing at -0.1067 and -0.1260 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Esperion Therapeutics Inc. (NASDAQ: ESPR), Northland Capital upgraded it to a Market perform rating. They previously had an Under perform rating on the stock.
